Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
Drugs by status
Approved for this indication (2)
Phase 4 trials (4)
Phase 3 trials (2)
Phase 2 trials (3)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (19)
- Banaras Hindu University
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Federal University of Minas Gerais
- University of Brasilia
- International Center for Diarrheal Disease Research
- Drugs for Neglected Diseases Initiative
- Federal University of Sergipe
- Federal University of Piaui
- Hospital Infantil Joao Paulo II - FHEMIG
- Federal University of Tocantins
- Rajendra Memorial Research Institute of Medical Sciences
- Kala-azar Medical Research Centre
- Shrimati Hazari Maternity and Medical Care
- Dr. A.K. Aditya Clinic
- University of Nagasaki
- Government of Brazil
- State University of Montes Claros
- PATH
- Medecins Sans Frontieres
Organization Involved with Phase 3 Indications (19)
- Bharat Serums and Vaccines Limited
- World Health Organization
- Addis Ababa University
- University of London
- Institute of Tropical Medicine, Belgium
- Kenya Medical Research Institute
- Makerere University
- Slotervaart Hospital
- University of Khartoum
- Institute of Endemic Diseases, Sudan
- Netherlands Cancer Institute
- University of Gondar
- Shaheed Suhrawardy Medical College
- Thrasher Research Fund
- Tigray Regional Health Bureau, Tigray Region
- Amhara Regional Health Bureau, Amhara Region
- Leishmania East Africa Platform
- University of Antwerp
- Government of Taiwan
Organization Involved with Phase 2 Indications (9)
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (2)